Literature DB >> 22473375

In vitro transcription and capping of Gaussia luciferase mRNA followed by HeLa cell transfection.

Bhairavi Jani1, Ryan Fuchs.   

Abstract

In vitro transcription is the synthesis of RNA transcripts by RNA polymerase from a linear DNA template containing the corresponding promoter sequence (T7, T3, SP6) and the gene to be transcribed (Figure 1A). A typical transcription reaction consists of the template DNA, RNA polymerase, ribonucleotide triphosphates, RNase inhibitor and buffer containing Mg(2+) ions. Large amounts of high quality RNA are often required for a variety of applications. Use of in vitro transcription has been reported for RNA structure and function studies such as splicing(1), RNAi experiments in mammalian cells(2), antisense RNA amplification by the "Eberwine method"(3), microarray analysis(4) and for RNA vaccine studies(5). The technique can also be used for producing radiolabeled and dye labeled probes(6). Warren, et al. recently reported reprogramming of human cells by transfection with in vitro transcribed capped RNA(7). The T7 High Yield RNA Synthesis Kit from New England Biolabs has been designed to synthesize up to 180 μg RNA per 20 μl reaction. RNA of length up to 10kb has been successfully transcribed using this kit. Linearized plasmid DNA, PCR products and synthetic DNA oligonucleotides can be used as templates for transcription as long as they have the T7 promoter sequence upstream of the gene to be transcribed. Addition of a 5' end cap structure to the RNA is an important process in eukaryotes. It is essential for RNA stability(8), efficient translation(9), nuclear transport(10) and splicing(11). The process involves addition of a 7-methylguanosine cap at the 5' triphosphate end of the RNA. RNA capping can be carried out post-transcriptionally using capping enzymes or co-transcriptionally using cap analogs. In the enzymatic method, the mRNA is capped using the Vaccinia virus capping enzyme(12,13). The enzyme adds on a 7-methylguanosine cap at the 5' end of the RNA using GTP and S-adenosyl methionine as donors (cap 0 structure). Both methods yield functionally active capped RNA suitable for transfection or other applications(14) such as generating viral genomic RNA for reverse-genetic systems(15) and crystallographic studies of cap binding proteins such as eIF4E(16). In the method described below, the T7 High Yield RNA Synthesis Kit from NEB is used to synthesize capped and uncapped RNA transcripts of Gaussia luciferase (GLuc) and Cypridina luciferase (CLuc). A portion of the uncapped GLuc RNA is capped using the Vaccinia Capping System (NEB). A linearized plasmid containing the GLuc or CLuc gene and T7 promoter is used as the template DNA. The transcribed RNA is transfected into HeLa cells and cell culture supernatants are assayed for luciferase activity. Capped CLuc RNA is used as the internal control to normalize GLuc expression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22473375      PMCID: PMC3460589          DOI: 10.3791/3702

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  20 in total

1.  Infectious RNA transcribed in vitro from a cDNA copy of the human coronavirus genome cloned in vaccinia virus.

Authors:  Volker Thiel; Jens Herold; Barbara Schelle; Stuart G Siddell
Journal:  J Gen Virol       Date:  2001-06       Impact factor: 3.891

2.  RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase.

Authors:  Olivier Donzé; Didier Picard
Journal:  Nucleic Acids Res       Date:  2002-05-15       Impact factor: 16.971

Review 3.  Cap and cap-binding proteins in the control of gene expression.

Authors:  Ivan Topisirovic; Yuri V Svitkin; Nahum Sonenberg; Aaron J Shatkin
Journal:  Wiley Interdiscip Rev RNA       Date:  2010-10-28       Impact factor: 9.957

4.  Cocrystal structure of the messenger RNA 5' cap-binding protein (eIF4E) bound to 7-methyl-GDP.

Authors:  J Marcotrigiano; A C Gingras; N Sonenberg; S K Burley
Journal:  Cell       Date:  1997-06-13       Impact factor: 41.582

5.  Concurrent splicing and transcription are not sufficient to enhance splicing efficiency.

Authors:  Denis Lazarev; James L Manley
Journal:  RNA       Date:  2007-07-13       Impact factor: 4.942

6.  Synthesis and properties of mRNAs containing the novel "anti-reverse" cap analogs 7-methyl(3'-O-methyl)GpppG and 7-methyl (3'-deoxy)GpppG.

Authors:  J Stepinski; C Waddell; R Stolarski; E Darzynkiewicz; R E Rhoads
Journal:  RNA       Date:  2001-10       Impact factor: 4.942

Review 7.  The role of the cap structure in RNA processing and nuclear export.

Authors:  J D Lewis; E Izaurralde
Journal:  Eur J Biochem       Date:  1997-07-15

8.  Cap ribose methylation of c-mos mRNA stimulates translation and oocyte maturation in Xenopus laevis.

Authors:  H Kuge; G G Brownlee; P D Gershon; J D Richter
Journal:  Nucleic Acids Res       Date:  1998-07-01       Impact factor: 16.971

9.  Synthesis of adenosine derivatives as transcription initiators and preparation of 5' fluorescein- and biotin-labeled RNA through one-step in vitro transcription.

Authors:  Faqing Huang; Guocan Wang; Tricia Coleman; Na Li
Journal:  RNA       Date:  2003-12       Impact factor: 4.942

10.  Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA.

Authors:  Luigi Warren; Philip D Manos; Tim Ahfeldt; Yuin-Han Loh; Hu Li; Frank Lau; Wataru Ebina; Pankaj K Mandal; Zachary D Smith; Alexander Meissner; George Q Daley; Andrew S Brack; James J Collins; Chad Cowan; Thorsten M Schlaeger; Derrick J Rossi
Journal:  Cell Stem Cell       Date:  2010-09-30       Impact factor: 24.633

View more
  5 in total

1.  Cap analog and Potato virus A HC-Pro silencing suppressor improve GFP transient expression using an infectious virus vector in Nicotiana benthamiana.

Authors:  Amin-Alah Tahmasebi; Alireza Afsharifar
Journal:  Mol Biol Res Commun       Date:  2017-06

Review 2.  mRNA vaccine: a potential therapeutic strategy.

Authors:  Yang Wang; Ziqi Zhang; Jingwen Luo; Xuejiao Han; Yuquan Wei; Xiawei Wei
Journal:  Mol Cancer       Date:  2021-02-16       Impact factor: 27.401

Review 3.  The potential of RNA-based therapy for kidney diseases.

Authors:  Tjessa Bondue; Lambertus van den Heuvel; Elena Levtchenko; Roland Brock
Journal:  Pediatr Nephrol       Date:  2022-05-04       Impact factor: 3.651

4.  Application of the SSB biosensor to study in vitro transcription.

Authors:  Alexander Cook; Yukti Hari-Gupta; Christopher P Toseland
Journal:  Biochem Biophys Res Commun       Date:  2018-01-31       Impact factor: 3.575

Review 5.  Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency.

Authors:  Sun Chang Kim; Simranjeet Singh Sekhon; Woo-Ri Shin; Gna Ahn; Byung-Kwan Cho; Ji-Young Ahn; Yang-Hoon Kim
Journal:  Mol Cell Toxicol       Date:  2021-09-20       Impact factor: 1.080

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.